Dr. Chen Wenjia is an assistant professor at Saw Swee Hock School of Public Health, National University of Singapore since 2021. She obtained her PhD degree in Health Economics and Outcomes Research from University of British Columbia, Canada in 2016. With an ultimate goal to address the complexity of care and treatment in chronic diseases that ensures the sustainability of our healthcare system, Dr Chen’s research program aims to apply big data analytics to generate cutting-edge real-world evidence to support personalised, ‘systems’ care of chronic diseases and multi-morbidity. Her current projects include the development of AI-based clinical decision support e-tools for chronic respiratory conditions, economic evaluation of precision medicine and AI-empowered digital health technologies, prediction of policy influence on long-term economics of chronic respiratory disease. Recently, she has published important relevant papers in high impact clinical and policy journals, such as the 20-year individualized COPD risk predictor in Chest and methodological challenges in economic evaluation of precision medicine in Value in Health.

Kelly Lenahan is the Director of Global HTA Initiatives at ISPOR – the professional society for health economics and outcomes research. She has been responsible for all the global health technology assessment activities at ISPOR since 2015. She collaborates with local experts to hold HTA Roundtables in 5 major regions of the globe. Kelly has a passion for sharing information and helping to make connections globally, especially in low- and middle-income countries, to improve healthcare systems and health technology assessment processes. She received her Master’s in Public Health with a concentration in Epidemiology from Rutgers University. Kelly has several publications about coverage restrictions for specialty drugs in the United States and received a Rising Star award from the Healthcare Businesswomen’s Association.

Mark Sculpher is Professor of Health Economics and Director of the Centre for Health Economics, University of York. He is also Co-Director of the Policy Research Unit in Economic Evaluation of Health and Care Interventions, a programme of research for the UK Department of Health and Social Care funded by the National Institute for Health Research (NIHR).

Mark has worked in the field of economic evaluation and health technology assessment for over 30 years. He has researched in a range of clinical areas including heart disease, cancer, diagnostics, and public health. He has also contributed to research methods in the field, in particular relating to decision analytic modelling and techniques to handle uncertainty, heterogeneity and generalisability. He is also experienced in economic analysis in low- and middle-income settings. He has over 300 peer-reviewed publications and is a co-author of two major textbooks in the area: Methods for the Economic Evaluation of Health Care Programmes (OUP, 2015 with Drummond, Claxton, Torrance and Stoddart) and Decision Modelling for Health Economic Evaluation (OUP, 2006 with Briggs and Claxton).

Mark is an emeritus member of the UK NIHR College of Senior Investigators. He has been a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee, the NICE Public Health Interventions Advisory Committee and NICE’s Diagnostics Advisory Committee. He has also been involved in advising NICE on methods over many years. Mark has also advised the UK House of Commons Health and Social Care Select Committee, as well as health systems internationally on health technology assessment methods including those in France, Ireland, Japan, Singapore, Germany, Portugal, Taiwan and New Zealand. He has been a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme, the UK NIHR /Medical Research Council’s Methodology Research Panel and the UK Department of Health’s Policy Research Programme’s Commissioning Panel. He served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2011-12). Mark is a Fellow of the UK Academy of Medical Sciences.

Yue Xiao, PhD in Management Science, Professor, senior Research Fellow, Director of the Research Unit on Application of Health Assessment & Evaluation, the China National Health Development Research Center, National Health Commission, P. R. China. Her research domains include application of evaluation and assessment in health reforms and development. She has promoted the development of HTA as a discipline as well as a system in China, and conducted quite a few key HTAs for the National Health Commission, covering medicines, medical devices, clinical procedures, and public health interventions, etc. She led the research and development of evaluation manuals on medicines and medical technologies, including artificial intelligence and medical equipment. She has worked as principal investigator or main investigator on over 60 national projects, including 5 major national science and technology development projects. She edited or coauthored 10 books, and published over 120 academic papers in key academic journals in Chinese and English.

Yot Teerawattananon is the founder of the Health Intervention and Technology Assessment Program (HITAP) at the Thai Ministry of Public Health and a visiting professor at the Saw Swee Hock School of Public Health, National University of Singapore. He is also a co-founder of the Health Technology Assessment (HTA) network in Asia, known as HTAsiaLink, and the international Decision Support Initiative (iDSI).

Dr. Yasuhriro Morii serves in roles in Japan's health research and policy landscape: as a researcher and a member of the International Division at the Centre for Outcomes Research and Economic Evaluation for Health (C2H) within the National Institute of Public Health (NIPH). The work at C2H is dedicated to evaluating medical drugs and medical devices for the cost-effectiveness evaluation in Japan, research and human resource development in the field of HTA.

Research Focus: His research fields include health economic assessment, cost-effectiveness analysis, quality of life research, and the development of patient-reported outcome measures, health services research such as geographical accessibility and equity of healthcare resources allocation.

Notable Projects: He has participated in collaborative initiatives, including the AP-7D (Asia PBM seven dimensions) project, working with colleagues to develop a preference-based measure for East and Southeast Asian populations.

International Engagement: He participates in international HTA collaborations through networks such as HTAsiaLink, HTAi, and INAHTA, learning from colleagues and sharing experiences across borders.

Dr. Jeonghoon Ahn is a full professor at the Ewha Womans University (Seoul, Korea) and an adjunct fellow at the National Evidence-based healthcare Collaborating Agency (NECA), Seoul, Korea. He is an expert on health technology assessment (HTA) and health economics. He worked 7 years in NECA and served in various decision making and advisory committees of public agencies such as the Health Insurance Review and Assessment Services (HIRA) and the Korean Centers for Disease Control (KCDC). Professor Ahn has graduated the Seoul National University Department of International Economics for undergraduate and master program. He also received a PhD in Economics from the University of Southern California (USC) and was an assistant professor of pharmaceutical economics and Policy at the USC. Dr. Ahn has served on international professional organizations such as ISPOR, HTAi, INAHTA, and HTAsiaLink. He cofounded a regional HTA agency network, the HTAsiaLink (www.htasialink.org) with other regional experts.

Dr Nan Luo is an Associate Professor in Saw Swee Hock School of Public Health (SSHSPH) and Yong Loo Lin School of Medicine at the National University of Singapore (NUS). Dr Luo’s main research interest and expertise is measurement of self-reported health status and well-being including patient-reported outcomes (PRO), health-related quality of life (HRQL), and health-state preferences. Dr Luo is internationally known for his research work on EQ-5D which is the mostly used HRQL instrument in health technology assessment worldwide.

Dr. Eri Hoshino serves in dual roles in Japan's health research and policy landscape: as Head of the International Division at the Centre for Outcomes Research and Economic Evaluation for Health (C2H) within the National Institute of Public Health (NIPH), and as Chief of the Division of Policy Evaluation in the Department of Health Policy at the National Centre for Child Health and Development.

Research Focus: She focuses on Health Technology Assessment (HTA) with an emphasis on pediatric and maternal health. Her work includes health economic evaluation, cost-effectiveness analysis, quality of life assessment, and the development of patient-reported outcome measures. She has contributed to HTA methodology that considers diverse cultural perspectives and has experience in conducting systematic reviews and meta-analyses.

Notable Projects: She has participated in collaborative initiatives, including the AP-7D (Asia PBM seven dimensions) project, working with colleagues to develop a preference-based measure for East and Southeast Asian populations. She also contributes to East Asian research on caregiver well-being measurement, collaborating with partners in Taiwan and South Korea on culturally sensitive assessment tools. As part of research teams studying pediatric medications, she has supported evidence-based pediatric healthcare. She has also been involved in developing assessment approaches for newborn screening programs in Japan.

International Engagement: She participates in international HTA collaborations through networks such as HTAsiaLink, HTAi, and INAHTA, learning from colleagues and sharing experiences across borders.